EU countries closely regulate pharmaceutical prices, whereas the US does not. This paper shows how price constraints affect the profitability, stock returns and R&D spending of EU and US firms. Compared with EU firms, US firms are more profitable, earn higher stock returns and spend more on R&D. We tested the relationship between price regulation and R&D spending, and estimated the costs of tight EU price regulation. Although results show that EU consumers enjoyed much lower pharmaceutical price inflation, we estimated that price controls cost EU firms 46 fewer new medicines and 1680 fewer research jobs during our 19-year sample period. Had the US used controls similar to those used in the EU, we estimate it would have led to 117 fewer new medicines and 4368 fewer research jobs in the US.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2165/11535580-000000000-00000 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Two veterinary issues that look set to dominate 2025 - the ongoing Competition and Markets Authority investigation and access to veterinary medicines in Northern Ireland - featured high on the agenda at a hybrid online/in person BVA Council meeting on 11 December 2024.
View Article and Find Full Text PDFImpact of diagnosis-related group payment on medical expenditure and treatment efficiency on people with drug-resistant tuberculosis: a quasi-experimental study design.
Int J Equity Health
January 2025
Department of Health Management, School of Medicine and Health Management, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Background: The severe health challenge and financial burden of drug-resistant tuberculosis (DR-TB) continues to be an impediment in China and worldwide. This study aimed to explore the impact of Diagnosis-related group (DRG) payment on medical expenditure and treatment efficiency among DR-TB patients.
Methods: This retrospective cohort study included all DR-TB patients from the digitized Hospital Information System (HIS) of Wuhan Pulmonary Hospital and the TB Information Management System (TBIMS) with completed full course of National Tuberculosis Program (NTP) standard treatment in Wuhan from January 2016 to December 2022, excluding patients whose treatment spanned both before and after the DRG timepoint.
Pursuing healthy homeownership: an evaluation of the neighborhood health trajectories of shared equity homeowners.
BMC Public Health
January 2025
Department of Health Policy and Management, Fielding School of Public Health at UCLA, Box 951772, Los Angeles, CA, 90095-1772, USA.
Background: Shared equity homeownership - a model in which low- and moderate-income households purchase homes at affordable prices on the condition that the houses remain affordable upon resale - has been shown to produce several health-enhancing housing outcomes. These include permanent affordability, housing stability, and modest wealth-building. However, studies suggest low- and moderate-income households may sacrifice neighborhood quality when becoming homeowners, which can undermine the health benefits of homeownership.
View Article and Find Full Text PDFFine-mapping causal tissues and genes at disease-associated loci.
Nat Genet
January 2025
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Complex diseases often have distinct mechanisms spanning multiple tissues. We propose tissue-gene fine-mapping (TGFM), which infers the posterior inclusion probability (PIP) for each gene-tissue pair to mediate a disease locus by analyzing summary statistics and expression quantitative trait loci (eQTL) data; TGFM also assigns PIPs to non-mediated variants. TGFM accounts for co-regulation across genes and tissues and models uncertainty in cis-predicted expression models, enabling correct calibration.
View Article and Find Full Text PDFUnveiling chemical industry secrets: Insights gleaned from scientific literatures that examine internal chemical corporate documents-A scoping review.
PLoS One
January 2025
School of Public Policy and Administration, Carleton University, Ottawa, Canada.
Objective: Examine peer-reviewed scientific articles that used internal industry documents in the chemical sector to reveal corporate influence. Summarize sources of internal documents used in prior scientific papers to identify ongoing corporate strategies within the chemical field. Compare the corporate strategies identified in the chemical sector with the ones identified already identified in the pharmaceutical sector.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!